

Terumo Appoints the Candidates for Directors

TOKYO, JAPAN – May 14, 2024 – Terumo Corporation (TSE: 4543) hereby announces that it has decided the candidates for directors as below. The elections are subject to the approval of the Annual General Meeting of Shareholders to be held on June 26, 2024.

1. Candidates for directors

(Excluding directors who serve as Audit and Supervisory Committee

Members)

Name	New position	Current position
Toshiaki Takagi	Chairman of the Board	Same as on the left
Hikaru Samejima	Representative Director and Chief Executive Officer	Chief Executive Officer
Toshihiko Osada	Director and Group Senior Managing Executive Officer	Group Senior Managing Executive Officer
Kazunori Hirose	Director and Group Managing Executive Officer	Same as on the left
Norimasa Kunimoto	Director and Group Managing Executive Officer	Same as on the left
Hidenori Nishi	Independent Director	Same as on the left
Keiya Ozawa	Independent Director	Same as on the left
Mari Kogiso	Independent Director	(New candidate)

2. New Candidate for directors

Hikaru Samejima: Chief Executive Officer

Name	Professional Career
Hikaru Samejima (Born on May 27, 1964)	April 1988 Joined Toa Nenryo Kogyo Corporation (now ENEOS Corporation)
	February 2001 Joined Citi Bank N.A.
	January 2002 Joined the Company
	June 2007 President, Terumo Interventional Systems (Global), Cardiac and Vascular Group
	April 2014 Executive Officer Division President, Interventional Systems Division, Cardiac and Vascular Company
	April 2016 Senior Executive Officer
	April 2017 President, Cardiac and Vascular Company

	April 2018	Managing Executive Officer
	April 2020	President, General Hospital Company (now Medical Care Solutions Company)
	April 2022	Group Senior Managing Executive Officer
	April 2024	Chief Executive Officer (current)

Toshihiko Osada: Group Senior Managing Executive Officer

Name	Professional Career	
Toshihiko Osada (Born on January 28, 1967)	April 1989	Joined the Company
	January 2016	General Manager, Strategic Planning Department
	April 2016	Executive Officer
	April 2018	Senior Executive Officer
	April 2020	Managing Executive Officer
		President, Cardiac and Vascular Company
		Division President, Interventional Systems Division, Cardiac and Vascular Company
	April 2022	Group Senior Managing Executive Officer (current)
	April 2024	In charge of Innovation; R&D Division (CTO Office, Innovation Center, Technology Coordination Office, R&D Administration Department), DX Promotion Department, Intellectual Property Department, Clinical Development Department, Terumo Medical Pranex (current)

Mari Kogiso: Founder and CEO, SDG Impact Japan Inc.

Name	Professional Career	
Mari Kogiso (Born on November 15, 1966)	April 1990	Joined Long-Term Credit Bank of Japan, Limited
	June 1998	Joined World Bank
	June 2003	Representative, Asia, Multilateral Investment Guarantee Agency, World Bank Group
	October 2012	Founder and CEO, I Incubate Corporation
	October 2014	Representative, Dalberg Japan
	January 2016	Head of International Business Planning, Sasakawa Peace Foundation
	July 2017	General Manager, Gender Investment and Innovation Division, Sasakawa Peace Foundation
	June 2019	General Manager, CEO Office, FAST RETAILING CO., LTD.
	January 2021	Founder and CEO, SDG Impact Japan Inc. (current)
June 2022	Independent Audit & Supervisory Board Members, Mitsubishi	

3. Director to resign from the Board

Shinjiro Sato

Shoji Hatano

Yukiko Kuroda

About Terumo

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.